Skip to main content
Clinical Trials/JPRN-UMIN000036497
JPRN-UMIN000036497
Completed
N/A

Validation study of the efficacy of frailty discriminant score (FDS) in patients with urological cancers - Validation study of the efficacy of frailty discriminant score (FDS) in patients with urological cancers

Hirosaki Univ. School of Med.0 sites559 target enrollmentApril 14, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
rological cancers (Prostate cancer: PC, bladder cancer: BC, upper tract urothelial carcinoma: UTUC, renal cell carcinoma: RCC) Controls (Ctrl) Subjects who participated in the general health survey in the IWAKI health promotion project between 2013 and 2018.
Sponsor
Hirosaki Univ. School of Med.
Enrollment
559
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The frailty discriminant score (FDS) is a reliable and valid tool for assessing frailty and prognosis in patients with urological cancers.

Registry
who.int
Start Date
April 14, 2019
End Date
July 31, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hirosaki Univ. School of Med.

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Key exclusion criteria: 1\) patients with cancer except for PC, BC, UTUC, or RCC. 2\) patients with severe general condition who could not evaluate the frailty using FDS. Controls (Ctrl)

Outcomes

Primary Outcomes

Not specified

Similar Trials